CONMED (CNMD) Projected to Post Earnings on Wednesday

CONMED (NYSE:CNMD) is expected to be announcing its Q4 2025 results after the market closes on Wednesday, January 28th. Analysts expect the company to announce earnings of $1.32 per share and revenue of $366.8820 million for the quarter. CONMED has set its FY 2025 guidance at 4.480-4.530 EPS. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, January 28, 2026 at 4:30 PM ET.

CONMED (NYSE:CNMD) last released its earnings results on Wednesday, November 5th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. The company had revenue of $337.93 million for the quarter, compared to analyst estimates of $334.76 million. CONMED had a net margin of 4.75% and a return on equity of 14.22%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.05 EPS. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Stock Performance

CONMED stock opened at $41.64 on Wednesday. The firm has a fifty day simple moving average of $41.66 and a two-hundred day simple moving average of $46.95. The company has a quick ratio of 0.95, a current ratio of 2.10 and a debt-to-equity ratio of 0.85. CONMED has a twelve month low of $38.32 and a twelve month high of $74.70. The company has a market capitalization of $1.29 billion, a PE ratio of 20.31, a P/E/G ratio of 1.87 and a beta of 0.96.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Kelleher Financial Advisors purchased a new position in shares of CONMED during the third quarter valued at approximately $28,000. Quarry LP grew its stake in shares of CONMED by 244.8% in the 3rd quarter. Quarry LP now owns 869 shares of the company’s stock worth $41,000 after buying an additional 617 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new position in CONMED during the 3rd quarter valued at approximately $211,000. iSAM Funds UK Ltd purchased a new position in CONMED during the second quarter valued at $215,000. Finally, Tower Research Capital LLC TRC boosted its holdings in CONMED by 107.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,248 shares of the company’s stock worth $221,000 after acquiring an additional 2,205 shares in the last quarter.

Wall Street Analyst Weigh In

CNMD has been the subject of a number of recent research reports. Piper Sandler lowered their target price on CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. JPMorgan Chase & Co. decreased their price target on CONMED from $58.00 to $52.00 and set a “neutral” rating on the stock in a research note on Thursday, November 6th. Wells Fargo & Company lowered their price objective on CONMED from $57.00 to $47.00 and set an “equal weight” rating for the company in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d+)” rating on shares of CONMED in a report on Wednesday, October 8th. Finally, Bank of America decreased their target price on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating on the stock in a research note on Monday, December 8th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, CONMED currently has a consensus rating of “Reduce” and a consensus price target of $53.67.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.